Eyepoint Pharmaceuticals announces Phase 3 diabetes program starting in 2026

Eyepoint Pharmaceuticals announces Phase 3 diabetes program starting in 2026
@EyePointPharma: Eyepoint announces Phase 3 trials

Eyepoint Pharmaceuticals has announced an ambitious pivotal Phase 3 program targeting diabetic macular edema (DME).

The company anticipates dosing its first patient in the first quarter of 2026. This program is reinforced by new preclinical data, which suggests a multi-mechanism of action (MOA) targeted approach, potentially enhancing treatment efficacy. The promising preclinical findings will be presented at the Eyecelerator event during the American Academy of Ophthalmology's 2025 annual meeting. The announcement underscores Eyepoint's commitment to advancing treatment options for DME, a leading cause of vision loss among diabetics.

No output.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.